Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 4/20 | 0.43 |
| ▸ | CYCS | P99999 | 4/20 | 0.42 |
| ▸ | TERT | O14746 | 4/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18883145 | 0.92 | TOP1 (0.50) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL18883144 | 0.88 | TOP1 (0.43) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL26703548 | 0.86 | TERT (0.53) | TOP1CYCSTERTENPP2ABCG2 | |
| SCHEMBL4413776 | 0.85 | TOP1 (0.53) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL16270682 | 0.84 | CYCS (0.54) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL19326350 | 0.83 | TOP1 (0.49) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL16920361 | 0.81 | TOP1 (0.43) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL19901985 | 0.80 | TOP1 (0.60) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL16923752 | 0.80 | TOP1 (0.46) | TOP1CYCSTERTSTAT3STAT1 | |
| SCHEMBL16920365 | 0.80 | TOP1 (0.56) | TOP1CYCSTERTSTAT3STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143811-A1 | METHOD OF TREATING MELANOMA | PCI BIOTECH AS (NO) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143811-A1 | METHOD OF TREATING MELANOMA | CD47, HLA-DRB1, CD74 | TOP1 4132/4885CYCS 3661/4885TERT 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.